SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arena Pharmaceuticals (ARNA)
ARNA 99.990.0%Mar 15 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
From: Harold Engstrom6/3/2020 12:52:55 PM
1 Recommendation

Recommended By
Savant

   of 2274
 
Ozanimod news yesterday drove ARNA valuation up. IMO, there is much more to go. Etrasimod efficacy and safety were shown to be superior to Ozanimod in p2 trials - and Etrasimod has a much shorter half-life. Ralinepag and Etrasimod trials are still on track. Olorinab trial apparently will experience a 3 month delay but that is OK, I think. And ARNA will likely spin off a neurological-focused company when the time is right. I think the company has a good shot at being bought out at a premium within the next 2 years - but also think that if it operates independently then it will become one of the bigger biopharm companies. Hope all have been well here - R, J, and P especially! H
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News